mci review 2013
DESCRIPTION
MILD COGNITIVE IMPAIRMENTTRANSCRIPT
![Page 1: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/1.jpg)
Mild cognitive impairmentMild cognitive impairment
[MCI][MCI]
Prof Ashraf AbdouNeuropsychiatry dept
Alexandria univ
![Page 2: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/2.jpg)
Objectives•The concept of MCI•Criteria for diagnosis•Controversies about MCI•Prevalence of MCI•Outcome of MCI•Trials for treatment of
MCI
![Page 3: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/3.jpg)
Cogntive abilities and age
Cognition: means of acquiring and processing information about our selves and our worldIncludes memory and other functions
Cognitive abilities peak in 30s
Plateau through 50s, 60s
Slow decline late 70s
![Page 4: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/4.jpg)
Dementia
Memory deficit+
At least 1 other cognitive area affected
+Interfere with daily
activity
![Page 5: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/5.jpg)
Mrs Um Alsaad a 60-yrs old lady, housewife describing her cognitive health as good till 2 yrs ago she and her children noticed her difficulty recalling where she place objects, her forgetfulness about recent conversations and difficult in remembering names.
She can do all her duties outside and inside the home.
Her MMSE 27
![Page 6: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/6.jpg)
• Kral 1962; Benign senescent forgetfulness.
• NIMH 1986; Age-associated memory impairment (AAMI)
• Int Psychogeriatric association 1994; Age-associated cognitive decline (AACD)
• CSHA 1997; Cognitive impairment no-dementia (CIND)
• AAN 2001; Mild cognitive impairment (MCI)
Development of the concept of MCI
![Page 7: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/7.jpg)
13000 publications till now in pubmed
![Page 8: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/8.jpg)
NormalCognition
Prodromal Dementia
Dementia
Brain Aging
Mild CognitiveImpairment
Stable OrReversibleImpairment
OtherDementias
Alzheimer’sDisease
VascularDementia
Reversible
Mixed Mixed
MCI is Prodromal Dementia
![Page 9: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/9.jpg)
MCI criteria1. Memory complaint,
preferably corroborated by an informant
2. Objective memory impairment for age
3. Normal general cognitive function
4. Intact activity of daily living
5. Not demented
![Page 10: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/10.jpg)
Application of MCI criteria
First criteria refers to the subjective memory complaint.
What if the patient didn’t complaint?
![Page 11: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/11.jpg)
Application of MCI criteriaSecond criteria refers to an
objective memory impairment for age.
–score 1-2 SD below their age-mates
MMSE low sensitivity for MCI
Montreal cognitive assessment [MoCA]
http://www.Mocatest.org
![Page 12: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/12.jpg)
• Third criteria regarding general intellectual function. - General intellectual function ( other nonmemory cognitive domains, e.g. language, executive function, visuospatial skills ) - n o specific instruments or cutoff scores - Neuropsychological testing can be very useful
Application of MCI criteria
![Page 13: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/13.jpg)
• Fourth: A ctivities of daily living The criterion requires that the
No f unctional impairment can be difficult to determine in older s
ubjects who may have several me dical comorbidities and physical li
mitations. • L ast criteria , 'not demented', is
also made on the basis of the clini cian's best judgement.
Application of MCI criteria
![Page 14: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/14.jpg)
Prevalence
P revalence of mild cognitive impairment
vary from1 34% to %•Increase with age•Different assessment tools
![Page 15: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/15.jpg)
Prevalence of MCIPrevalence of MCIAuthor (year)Author (year) N N Age Study Age Study Prevalence Prevalence
(%)(%)
Graham (1997) 1800 >65 CSHAGraham (1997) 1800 >65 CSHA 5.3 5.3
Larrieu (2002)Larrieu (2002) 1265 70-90 PAQUID 1265 70-90 PAQUID 2.8 2.8
Hanninen (2002) 806 60-76 KUPIOHanninen (2002) 806 60-76 KUPIO 5.3 5.3
Lopez (2003) 2470 >75 CHSLopez (2003) 2470 >75 CHS 6.06.0
Fisk (2003) 1790 >65 CSHAFisk (2003) 1790 >65 CSHA 1-31-3
Ganguli (2004) 1248 >65 MoVIESGanguli (2004) 1248 >65 MoVIES 3-4 3-4
![Page 16: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/16.jpg)
• Typical MCI patient is one who has a memory impairment beyond what is felt to be normal for age but is relatively intact in other cognitive domains.
• The concept of MCI has been expanded to include other types of cognitive impairment beyond memory
Clinical Spectrum
![Page 17: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/17.jpg)
Classification of MCI
MCI
Amnestic Non-amnestic
Single domain Multiple domainSingle domain
Multiple domain
![Page 18: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/18.jpg)
Clinical subtypes of mild cognitive impairment
![Page 19: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/19.jpg)
Flow chart of decision process for makingdiagnosis of subtypes of MCI
Journal of Internal MedicineVol 256 Issue 3 Page 183, Sep2004
![Page 20: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/20.jpg)
Exclusion of systemic or brain diseases that can cause cognitive decline
Depression - Memory function may improve with
treatment of depressionMetabolic disturbance
- Memory function may improve if correctedTraumatic injury
- Memory function often stabilizes after a period of recovery
Vascular disease - Memory function may stabilize or progress
![Page 21: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/21.jpg)
Outcome of MCIOutcome of MCI
MCI
AD
Age
Cog
nitiv
e D
eclin
e
![Page 22: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/22.jpg)
The annual rate of conversion to AD
10 – 15% per year
Outcome
![Page 23: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/23.jpg)
FunctionFunction
AgeAge
Probable ADProbable AD
MCI Amnestic TypeMCI Amnestic Type
NormalNormal
Conversion to AD
Definite ADDefinite AD
Point of conversion
![Page 24: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/24.jpg)
Outcome
Mayo Alzheimer's Disease Research Center
- 220, mean age 79 yrs, F/U 3-6 yrs
- Progressed from normal to
dementia at a rate of 12% per year
• Followed for up to 6 years approximately 80% of them will have converted to dementia
![Page 25: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/25.jpg)
Mild Cognitive Impairment Mild Cognitive Impairment (MCI)(MCI)
MCI →AD 12%/yr Control→AD 1-2%/yr
Petersen RC et al: Arch Neurol 56:303-308, 1999
50
60
70
80
90
100
50
60
70
80
90
100
Initial 12 24 36 48exam Months
Initial 12 24 36 48exam Months
![Page 26: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/26.jpg)
Clinical severity
Type; multiple domain vs single domain
Genetics: Apolipoprtein E-4 carrier
Biomarkers
Radiological
CSF
Outcome
![Page 27: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/27.jpg)
Neuroimaging
Essential part of general evaluation in MCI subject
- Identifying specific and treatable cause of cognitive impairment (DDx)
- Markers for prediction of conversion to AD
![Page 28: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/28.jpg)
Predict future development of AD
- Atrophy Hippocampus & entorhinal cortex ( MRI ) - Evidence deficits in - regional cerebral blood flow as measured by SPECT - regional cerebral glucose as measured by FDG-PET
Neuroimaging
![Page 29: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/29.jpg)
Arrow highlights the body of the hippocampus. Image on right is from a patient w
ith atrophy.
![Page 30: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/30.jpg)
Arrows mark the entorhinal cortex on MRIArrows mark the entorhinal cortex on MRI.
![Page 31: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/31.jpg)
(CSF) biomarkers
• Invasive procedure•Lack of normative data
no change of these CSF markers with age
•Effect of drugs on change in CSF markers
![Page 32: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/32.jpg)
(CSF) biomarkers
3 cerebrospinal fluid (CSF) biomarkers
- - -total tau (T )
- - -phospho tau (P )
- 42 amino acid form of β- amyloid
(Aβ42)
![Page 33: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/33.jpg)
TREATMENT
![Page 34: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/34.jpg)
•Dopenzil-Vit E-Placebo study 2005
•Galantamine trial; 2004•Rivastigmine trial; 2004•Rofecoxib trial; 2005•Ginko biloba; 2008• 12Folic acid vitamin B trial;
2004• Lithium; some benefit 2011
Fail to show any benefit
Treatment
![Page 35: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/35.jpg)
What to do?
• Exercise
• Healthy food
• Cognitive stimulating activities
• Stop smoking
• Control; DM, HTN, Dyslipedemia
• Treat depression
![Page 36: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/36.jpg)
Tying it all together!Tying it all together!
MCI is a widely MCI is a widely accepted term for accepted term for diagnosis of diagnosis of memory memory impairment not impairment not fulfilling the fulfilling the criteria of dementiacriteria of dementia
Diagnostic criteria Diagnostic criteria need to be need to be standardized, to standardized, to include it in the include it in the current current classifications.classifications.
![Page 37: MCI REVIEW 2013](https://reader035.vdocuments.site/reader035/viewer/2022081414/54bf0f6e4a7959354e8b4574/html5/thumbnails/37.jpg)
Tying it all together!Tying it all together!
Biomarkers are Biomarkers are the main focus of the main focus of research nowresearch now
Current treatment Current treatment options are options are control of risk control of risk factors and factors and healthy lifestylehealthy lifestyle